Developer docs
API playgroundTry for free, no card

Search company profiles

Alvion Pharmaceuticals SMSA

Full company profile

uuid000bcld

Namestring
Alvion Pharmaceuticals SMSA
Legal namestring
Alvion Pharmaceuticals Single Member S.A.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Alvion Pharmaceuticals SMSA is a privately held, science-oriented pharmaceutical company headquartered in Athens, Greece (Pallini, Attika), with regional offices in Galway, Ireland and Durban, South Africa. The company develops and manufactures non-infringing generic medicines — focusing on difficult-to-formulate products such as extended-release and fixed-combination formulations — often backed by formulation patents. Its core commercialized assets include Ticagrelor film coated tablets (a generic equivalent to Brilique, for prevention of major adverse cardiac events) and Mirabegron Prolonged Release tablets (a generic equivalent to MYRBETRIQ for overactive bladder), with EU eCTD dossiers and DCP filings in progress or completed for European market entry.

The company operates an asset-light, B2B out-licensing and supply model: Alvion develops formulations, secures regulatory dossiers and formulation IP, and licenses finished products or supply rights to 90+ pharmaceutical companies across 40+ countries spanning Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia. Revenue is generated through licensing royalties and one-time license/supply agreements. The company is described as an IP powerhouse providing licensing rights to the largest pharmaceutical companies globally.

Alvion's strategic positioning is to be first-to-market at or before patent expiry by developing non-infringing formulations that sidestep originator patents. It pursues this via co-development partnerships (notably V-Ensure Pharma Technologies for complex generics) and regional distribution agreements (notably Lupin Limited for Southeast Asia). In April 2026, the company received a strategic investment from iGrow Venture Partners VC, earmarked for R&D acceleration and global footprint expansion. Leadership comprises John Bouros as CEO and Marina Ioannidou as Corporate Communications Head; the company employs 11-50 staff and remains privately held with no public revenue disclosure.

Short descriptiontext

Alvion Pharmaceuticals is a privately held Greek pharmaceutical company that develops non-infringing, complex generic medicines and out-licenses them to 90+ pharmaceutical partners across 40+ countries in Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, non-infringing formulations, pharmaceutical out-licensing, complex generics, extended-release formulations
Industry2 codes
PRIMARYHLAIABAB
Complex Generics (e.g., inhalation, transdermal, liposomal)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing of proprietary products
TypeLicensing Royalties
Description

Alvion develops and licenses its proprietary generic medicines to leading pharmaceutical companies. Out-licensing of proprietaries and supplying these medicines is the core business of the group.

alvionpharma.com
2Supply agreements
TypeOne Time License
Description

Supply of manufactured medicines to pharmaceutical partners via both proprietary and supply licensing agreements

alvionpharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alvion develops and manufactures non-infringing generic medicines, including Ticagrelor film coated tablets and Mirabegron Prolonged Release tablets, and out-licenses these proprietary formulations to leading pharmaceutical companies worldwide. The company focuses on difficult-to-develop generics with proprietary formulation technologies, often patented, and operates through B2B licensing and supply agreements across 40+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Delivering medicines to millions of patients globally
Product overview1 text field

Alvion Pharmaceuticals is a science-oriented pharmaceutical company that develops and manufactures non-infringing generic medicines in Europe. The company operates as a vertically integrated pharmaceutical organization offering a portfolio of added-value generic medicines across therapeutic categories including cardiovascular, diabetes, urinary, and central nervous system. The core products include Ticagrelor Film Coated Tablets (cardiovascular) and Mirabegron PR Tablets (urinary/overactive bladder), which are out-licensed to leading pharmaceutical companies worldwide. Alvion focuses on difficult-to-develop products using non-infringing formulations, often backed by formulation patents, with emphasis on fixed combination technologies and extended-release formulations.

Product and service2 records
1Ticagrelor Film Coated Tablets
CategoryCardiovascular generic medicine
Description

Generic medicine equivalent to Brilique (AstraZeneca), used for prevention of stroke, heart attack and other events in patients with acute coronary syndrome; reduces risk of major adverse cardiac events (MACE) in myocardial infarction patients. Out-licensed to pharmaceutical partners across multiple regions.

2Mirabegron PR (Prolonged Release) Tablets
CategoryUrology generic medicine
Description

Generic medicine equivalent to MYRBETRIQ (Astellas), indicated for treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Available in 25mg and 50mg strengths and protected by proprietary non-infringing formulation patents.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-04-05
Description

Licensing agreement for commercialization of cardiometabolic medicines in Southeast Asia region (Malaysia, Vietnam). Lupin committed to providing new affordable treatment options and expanding footprint in the region with quality cost-effective alternatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner for complex generics formulations including Mirabegron Prolonged Release. V-Ensure is a fully integrated specialty pharma company with proprietary technology platforms and established R&D track record with successful delivery of over 150 formulations.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Stada is a European-focused generics and consumer health company with broad portfolio coverage across cardiovascular, urology and CNS. It shares Alvion's model of out-licensing and regional distribution partnerships across Europe and emerging markets.

TypeDirect peer
Description

Lupin is a major Indian-headquartered global generics and specialty pharma company and an existing licensing partner of Alvion for Southeast Asia. Both companies commercialize complex generics via out-licensing and regional distribution agreements, making Lupin a directly comparable generics player and channel partner.

TypeEmerging player
Description

Alvotech is a focused biosimilars and complex generics developer with a licensing-led commercial model similar to Alvion's. It shares Alvion's emphasis on difficult-to-develop formulations and partnerships with major pharma companies for global reach.

TypeDirect peer
Description

Apotex is one of the largest Canadian-owned generics manufacturers with global licensing reach. Its focus on complex generics and value-added formulations parallels Alvion's positioning around non-infringing and difficult-to-develop products.

TypeDirect peer
Description

Glenmark is an India-headquartered generics and specialty pharma company with licensing and distribution agreements across emerging markets. Its pipeline of complex generics and out-licensing deals in cardiovascular and CNS therapies aligns closely with Alvion's strategy.

TypeBroad incumbent
Description

Hikma is a multinational generics and specialty injectable manufacturer with strong presence in MENA, Europe and the US. Its MENA and European footprint overlaps materially with Alvion's geographic focus.

TypeBroad incumbent
Description

Viatris is a global generics and specialty pharma major formed from Mylan and Upjohn. It competes with Alvion in cardiovascular and urology generics across regulated and emerging markets via an extensive global distribution network.

8Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is the global generics and biosimilars arm of Novartis and one of the two largest pure-play generics companies worldwide. It offers overlapping capabilities with Alvion in complex generics across European and global markets as part of a much broader portfolio.

TypeDirect peer
Description

Polpharma is a Central European generics and OTC manufacturer with pan-European distribution and a portfolio of value-added generics. Its geographic concentration and licensing model across Eastern and Central Europe closely mirrors Alvion's European footprint.

TypeBroad incumbent
Description

Teva is the world's largest generics manufacturer with an extensive complex generics portfolio. It competes with Alvion across the same therapeutic areas but operates at far greater scale across R&D, manufacturing and global commercialization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alvion Pharmaceuticals SMSA

Generic Pharmaceuticalsalvionpharma.com

Alvion Pharmaceuticals is a privately held Greek pharmaceutical company that develops non-infringing, complex generic medicines and out-licenses them to 90+ pharmaceutical partners across 40+ countries in Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia.

What Alvion Pharmaceuticals SMSA does

Alvion Pharmaceuticals SMSA is a privately held, science-oriented pharmaceutical company headquartered in Athens, Greece (Pallini, Attika), with regional offices in Galway, Ireland and Durban, South Africa. The company develops and manufactures non-infringing generic medicines — focusing on difficult-to-formulate products such as extended-release and fixed-combination formulations — often backed by formulation patents. Its core commercialized assets include Ticagrelor film coated tablets (a generic equivalent to Brilique, for prevention of major adverse cardiac events) and Mirabegron Prolonged Release tablets (a generic equivalent to MYRBETRIQ for overactive bladder), with EU eCTD dossiers and DCP filings in progress or completed for European market entry.

The company operates an asset-light, B2B out-licensing and supply model: Alvion develops formulations, secures regulatory dossiers and formulation IP, and licenses finished products or supply rights to 90+ pharmaceutical companies across 40+ countries spanning Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia. Revenue is generated through licensing royalties and one-time license/supply agreements. The company is described as an IP powerhouse providing licensing rights to the largest pharmaceutical companies globally.

Alvion's strategic positioning is to be first-to-market at or before patent expiry by developing non-infringing formulations that sidestep originator patents. It pursues this via co-development partnerships (notably V-Ensure Pharma Technologies for complex generics) and regional distribution agreements (notably Lupin Limited for Southeast Asia). In April 2026, the company received a strategic investment from iGrow Venture Partners VC, earmarked for R&D acceleration and global footprint expansion. Leadership comprises John Bouros as CEO and Marina Ioannidou as Corporate Communications Head; the company employs 11-50 staff and remains privately held with no public revenue disclosure.

Alvion Pharmaceuticals SMSA firmographics

Firmographics
Name
Alvion Pharmaceuticals SMSA
Legal name
Alvion Pharmaceuticals Single Member S.A.
Website
https://alvionpharma.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Alvion Pharmaceuticals is a privately held Greek pharmaceutical company that develops non-infringing, complex generic medicines and out-licenses them to 90+ pharmaceutical partners across 40+ countries in Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia.
Ownership category
akta.pro rank

Alvion Pharmaceuticals SMSA industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAB
Complex Generics (e.g., inhalation, transdermal, liposomal)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Generic pharmaceuticals
  • Non-infringing formulations
  • Pharmaceutical out-licensing
  • Complex generics
  • Extended-release formulations

Where Alvion Pharmaceuticals SMSA is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices3 records

Markets served

Alvion Pharmaceuticals SMSA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Others

Revenue model

  1. Out-licensing of proprietary products: Alvion develops and licenses its proprietary generic medicines to leading pharmaceutical companies. Out-licensing of proprietaries and supplying these medicines is the core business of the group.
  2. Supply agreements: Supply of manufactured medicines to pharmaceutical partners via both proprietary and supply licensing agreements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Alvion Pharmaceuticals SMSA product offering

Product offering

Core offering

Alvion develops and manufactures non-infringing generic medicines, including Ticagrelor film coated tablets and Mirabegron Prolonged Release tablets, and out-licenses these proprietary formulations to leading pharmaceutical companies worldwide. The company focuses on difficult-to-develop generics with proprietary formulation technologies, often patented, and operates through B2B licensing and supply agreements across 40+ countries.

Product overview

Alvion Pharmaceuticals is a science-oriented pharmaceutical company that develops and manufactures non-infringing generic medicines in Europe. The company operates as a vertically integrated pharmaceutical organization offering a portfolio of added-value generic medicines across therapeutic categories including cardiovascular, diabetes, urinary, and central nervous system. The core products include Ticagrelor Film Coated Tablets (cardiovascular) and Mirabegron PR Tablets (urinary/overactive bladder), which are out-licensed to leading pharmaceutical companies worldwide. Alvion focuses on difficult-to-develop products using non-infringing formulations, often backed by formulation patents, with emphasis on fixed combination technologies and extended-release formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ticagrelor Film Coated Tablets Generic medicine equivalent to Brilique (AstraZeneca), used for prevention of stroke, heart attack and other events in patients with acute coronary syndrome; reduces risk of major adverse cardiac events (MACE) in myocardial infarction patients. Out-licensed to pharmaceutical partners across multiple regions.
  • Mirabegron PR (Prolonged Release) Tablets Generic medicine equivalent to MYRBETRIQ (Astellas), indicated for treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Available in 25mg and 50mg strengths and protected by proprietary non-infringing formulation patents.

Quantifiable outcome

  • Delivering medicines to millions of patients globally

Companies that use Alvion Pharmaceuticals SMSA

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Alvion Pharmaceuticals SMSA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alvion Pharmaceuticals SMSA partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major and core.

  • Lupin LimitedmajorChannel Partner/ Reseller/ Distributor · 5 April 2022Licensing agreement for commercialization of cardiometabolic medicines in Southeast Asia region (Malaysia, Vietnam). Lupin committed to providing new affordable treatment options and expanding footprint in the region with quality cost-effective alternatives.
  • V-Ensure Pharma TechnologiescoreStrategic or Co-development PartnerCo-development partner for complex generics formulations including Mirabegron Prolonged Release. V-Ensure is a fully integrated specialty pharma company with proprietary technology platforms and established R&D track record with successful delivery of over 150 formulations.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Alvion Pharmaceuticals SMSA competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: Stada is a European-focused generics and consumer health company with broad portfolio coverage across cardiovascular, urology and CNS. It shares Alvion's model of out-licensing and regional distribution partnerships across Europe and emerging markets.
  • Lupin Limited: Lupin is a major Indian-headquartered global generics and specialty pharma company and an existing licensing partner of Alvion for Southeast Asia. Both companies commercialize complex generics via out-licensing and regional distribution agreements, making Lupin a directly comparable generics player and channel partner.
  • Apotex: Apotex is one of the largest Canadian-owned generics manufacturers with global licensing reach. Its focus on complex generics and value-added formulations parallels Alvion's positioning around non-infringing and difficult-to-develop products.
  • Glenmark Pharmaceuticals: Glenmark is an India-headquartered generics and specialty pharma company with licensing and distribution agreements across emerging markets. Its pipeline of complex generics and out-licensing deals in cardiovascular and CNS therapies aligns closely with Alvion's strategy.
  • Polpharma: Polpharma is a Central European generics and OTC manufacturer with pan-European distribution and a portfolio of value-added generics. Its geographic concentration and licensing model across Eastern and Central Europe closely mirrors Alvion's European footprint.

Emerging players

  • Alvotech: Alvotech is a focused biosimilars and complex generics developer with a licensing-led commercial model similar to Alvion's. It shares Alvion's emphasis on difficult-to-develop formulations and partnerships with major pharma companies for global reach.

Broad incumbents

  • Hikma Pharmaceuticals: Hikma is a multinational generics and specialty injectable manufacturer with strong presence in MENA, Europe and the US. Its MENA and European footprint overlaps materially with Alvion's geographic focus.
  • Viatris: Viatris is a global generics and specialty pharma major formed from Mylan and Upjohn. It competes with Alvion in cardiovascular and urology generics across regulated and emerging markets via an extensive global distribution network.
  • Sandoz (Novartis): Sandoz is the global generics and biosimilars arm of Novartis and one of the two largest pure-play generics companies worldwide. It offers overlapping capabilities with Alvion in complex generics across European and global markets as part of a much broader portfolio.
  • Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer with an extensive complex generics portfolio. It competes with Alvion across the same therapeutic areas but operates at far greater scale across R&D, manufacturing and global commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Alvion Pharmaceuticals SMSA social profiles

Digital presence

Alvion Pharmaceuticals SMSA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alvion Pharmaceuticals SMSA leadership team

Management profile

Number of profiles

Profiles2 records

Alvion Pharmaceuticals SMSA funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alvion Pharmaceuticals SMSA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alvion Pharmaceuticals SMSA

What does Alvion Pharmaceuticals SMSA do?

Alvion develops and manufactures non-infringing generic medicines, including Ticagrelor film coated tablets and Mirabegron Prolonged Release tablets, and out-licenses these proprietary formulations to leading pharmaceutical companies worldwide. The company focuses on difficult-to-develop generics with proprietary formulation technologies, often patented, and operates through B2B licensing and supply agreements across 40+ countries.

Is Alvion Pharmaceuticals SMSA a public or private company?

Alvion Pharmaceuticals SMSA is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alvion Pharmaceuticals SMSA founded?

Alvion Pharmaceuticals SMSA was founded in 2013. It employs 11 to 50 people.

Where is Alvion Pharmaceuticals SMSA based?

Alvion Pharmaceuticals SMSA is headquartered in Athens, Greece, in the Europe region.

How does Alvion Pharmaceuticals SMSA make money?

Two revenue lines are on record. Out-licensing of proprietary products are the primary driver. The others are supply agreements.

Who are Alvion Pharmaceuticals SMSA's main competitors?

Direct peers on record are Stada Arzneimittel, Lupin Limited, Apotex, Glenmark Pharmaceuticals and Polpharma. Alvotech is listed as an emerging player. Broad incumbents are Hikma Pharmaceuticals, Viatris, Sandoz (Novartis) and Teva Pharmaceutical Industries.

Does Alvion Pharmaceuticals SMSA have an API?

No public API is recorded for Alvion Pharmaceuticals SMSA.

What industry is Alvion Pharmaceuticals SMSA in?

Alvion Pharmaceuticals SMSA's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAB, Complex Generics (e.g., inhalation, transdermal, liposomal), with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals